Neurol. praxi 2017; 18(Suppl F): 22-24 | DOI: 10.36290/neu.2017.125

First line therapy and pregnancy in patients with multiple sclerosis – case reports

MUDr. Marko Petržalka
Neurologická klinika 2. LF UK a FN Motol, Praha

Multiple sclerosis is a chronic autoimmune neurodegenerative disease that affects predominantly young females in age spanbetween 20 and 40 years. Most of the patients would thus be in childbearing age. This article provides an insight into the therapyof patients planning pregnancy and on two cases-reports demonstrates the real clinical experience.

Keywords: multiple sclerosis, pregnancy, interferon beta

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petržalka M. First line therapy and pregnancy in patients with multiple sclerosis – case reports. Neurol. praxi. 2017;18(Suppl.F - Aktuální pohled na...):22-24. doi: 10.36290/neu.2017.125.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M. Pregnancy and fetal outcomes after interferon-exposure in multiple sclerosis. Neurol 2010; 75: 1794-1802. Go to original source... Go to PubMed...
    2. Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg S?rensen P, Udd B. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008; 15: 893-908. Go to original source... Go to PubMed...
    3. Havrdová E, Meluzínová E, Nytrová P. Těhotenství a menopauza. Kapitola v: Roztroušená skleróza. Praha: Mladá fronta 2013: 418-419.
    4. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurol 2012; 79: 1130-1135. Go to original source... Go to PubMed...
    5. Product Information. Avonex (interferon beta-1a) [online]. 2016. Dostupný na WWW: https://www.avonex.com/content/dam/commercial/multiple-sclerosis/avonex/pat/en_us/pdf/Avonex_Prescribing_Information.pdf (accessed 28 Aug.2017).
    6. Rebif: EPAR - Product Information [online]. 2017. Dostupný na WWW: https://http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf (accessed 10 Nov.2017).
    7. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011; 17: 423-430. Go to original source... Go to PubMed...
    8. Špalek P. Intravenózny imunoglobulín v liečbe autoimunitných neurologických ochorení. Neurol. praxi 2011; 12: 383-387.
    9. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009; 15: 1037-1042. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.